SUBSCRIBE
SUBSCRIBE
News   Drug Development

Eli Lilly and Company’s Effient Tied in Study to Higher Rate of Cancer Risk Than Plavix

June 29, 2010 | 
1 min read
Bloomberg -- Eli Lilly’s blood-thinner Effient was linked to higher rates of cancer than Bristol-Myers Squibb Co.’s rival product Plavix, research published today found.
Clinical research Postmarket research
Eli Lilly and Company
MORE ON THIS TOPIC
Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
January 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Pros and cons collage. Mixed media thumbs up and thumbs down hand gestures with speech bubbles. Review concept, positive and negative feedback vector illustration.
Immunology and inflammation
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway
January 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Start early or business advantage. Businessman starts running ahead of competitors vector
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
January 22, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
January 22, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker